A polycomb repression signature in metastatic prostate cancer predicts cancer outcome - PubMed (original) (raw)

. 2007 Nov 15;67(22):10657-63.

doi: 10.1158/0008-5472.CAN-07-2498.

Jianjun Yu, Daniel R Rhodes, Scott A Tomlins, Xuhong Cao, Guoan Chen, Rohit Mehra, Xiaoju Wang, Debashis Ghosh, Rajal B Shah, Sooryanarayana Varambally, Kenneth J Pienta, Arul M Chinnaiyan

Affiliations

• PMID: 18006806
• DOI: 10.1158/0008-5472.CAN-07-2498

A polycomb repression signature in metastatic prostate cancer predicts cancer outcome

Jindan Yu et al. Cancer Res. 2007.

Abstract

The Polycomb Group (PcG) protein EZH2 is a critical component of a multiprotein complex that methylates Lys(27) of histone 3 (H3K27), which consequently leads to the repression of target gene expression. We have previously reported that EZH2 is overexpressed in metastatic prostate cancer and is a marker of aggressive diseases in clinically localized solid tumors. However, the global set of genes directly regulated by PcG in tumors is largely unknown, and thus how PcG mediates tumor progression remains unclear. Herein we mapped genome-wide H3K27 methylation in aggressive, disseminated human prostate cancer tissues. Integrative analysis revealed that a significant subset of these genes are also targets of PcG in embryonic stem cells, and their repression in tumors is associated with poor prognosis. By stepwise cross-validation, we developed a "Polycomb repression signature" composed of 14 direct targets of PcG in metastatic tumors. Notably, solid tumor subtypes in which this gene signature is repressed show poor clinical outcome in multiple microarray data sets of tumors including breast and prostate cancer. Taken together, our results show a fingerprint of PcG-mediated transcriptional repression in metastatic prostate cancer that is reminiscent of stem cells and associated with cancer progression. Therefore, PcG proteins play a central role in the epigenetic silencing of target genes and functionally link stem cells, metastasis, and cancer survival.

PubMed Disclaimer

Similar articles

• Concise review: roles of polycomb group proteins in development and disease: a stem cell perspective.
  Rajasekhar VK, Begemann M. Rajasekhar VK, et al. Stem Cells. 2007 Oct;25(10):2498-510. doi: 10.1634/stemcells.2006-0608. Epub 2007 Jun 28. Stem Cells. 2007. PMID: 17600113 Review.
• Transcriptional repression mediated by the human polycomb-group protein EED involves histone deacetylation.
  van der Vlag J, Otte AP. van der Vlag J, et al. Nat Genet. 1999 Dec;23(4):474-8. doi: 10.1038/70602. Nat Genet. 1999. PMID: 10581039
• The murine polycomb group protein Eed is required for global histone H3 lysine-27 methylation.
  Montgomery ND, Yee D, Chen A, Kalantry S, Chamberlain SJ, Otte AP, Magnuson T. Montgomery ND, et al. Curr Biol. 2005 May 24;15(10):942-7. doi: 10.1016/j.cub.2005.04.051. Curr Biol. 2005. PMID: 15916951
• Essential role for activation of the Polycomb group (PcG) protein chromatin silencing pathway in metastatic prostate cancer.
  Berezovska OP, Glinskii AB, Yang Z, Li XM, Hoffman RM, Glinsky GV. Berezovska OP, et al. Cell Cycle. 2006 Aug;5(16):1886-901. doi: 10.4161/cc.5.16.3222. Epub 2006 Aug 15. Cell Cycle. 2006. PMID: 16963837
• Epigenetic mechanisms in the biology of prostate cancer.
  Schulz WA, Hoffmann MJ. Schulz WA, et al. Semin Cancer Biol. 2009 Jun;19(3):172-80. doi: 10.1016/j.semcancer.2009.02.006. Epub 2009 Feb 20. Semin Cancer Biol. 2009. PMID: 19429481 Review.

Cited by

• Multifaceted role of EZH2 in breast and prostate tumorigenesis: epigenetics and beyond.
  Deb G, Thakur VS, Gupta S. Deb G, et al. Epigenetics. 2013 May;8(5):464-76. doi: 10.4161/epi.24532. Epub 2013 Apr 17. Epigenetics. 2013. PMID: 23644490 Free PMC article. Review.
• Androgen receptor epigenetics.
  Cai C, Yuan X, Balk SP. Cai C, et al. Transl Androl Urol. 2013 Sep 1;2(3):148-157. doi: 10.3978/j.issn.2223-4683.2013.09.02. Transl Androl Urol. 2013. PMID: 25580383 Free PMC article.
• The role of mutations in epigenetic regulators in myeloid malignancies.
  Shih AH, Abdel-Wahab O, Patel JP, Levine RL. Shih AH, et al. Nat Rev Cancer. 2012 Sep;12(9):599-612. doi: 10.1038/nrc3343. Epub 2012 Aug 17. Nat Rev Cancer. 2012. PMID: 22898539 Review.
• The role of YAP transcription coactivator in regulating stem cell self-renewal and differentiation.
  Lian I, Kim J, Okazawa H, Zhao J, Zhao B, Yu J, Chinnaiyan A, Israel MA, Goldstein LS, Abujarour R, Ding S, Guan KL. Lian I, et al. Genes Dev. 2010 Jun 1;24(11):1106-18. doi: 10.1101/gad.1903310. Genes Dev. 2010. PMID: 20516196 Free PMC article.
• Prognostic impact of H3K27me3 expression on locoregional progression after chemoradiotherapy in esophageal squamous cell carcinoma.
  He LR, Liu MZ, Li BK, Rao HL, Liao YJ, Guan XY, Zeng YX, Xie D. He LR, et al. BMC Cancer. 2009 Dec 22;9:461. doi: 10.1186/1471-2407-9-461. BMC Cancer. 2009. PMID: 20028503 Free PMC article.

Publication types

MeSH terms

Substances

LinkOut - more resources

• Full Text Sources

  • Silverchair Information Systems

• Other Literature Sources

  • H1 Connect - Access expert opinions and insights on biomedical research.
  • The Lens - Patent Citations Database

• Medical

  • MedlinePlus Health Information

• Molecular Biology Databases

  • NIAID Data Ecosystem - Find datasets on Infectious and Immune-mediated Diseases